Skip to content

Study · Not a test of the peptide alone · 2016

1 result

[The efficacy of combination therapy with mexidol and cerebrolysin in chronic cerebral ischemia].

Berezhnaya SV, Yakupov EZ, Zaharov YA

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2016Cited by 3 (Europe PMC)

PMID27240176 (opens in a new tab)DOI10.17116/jnevro20161165123-27 (opens in a new tab)PepBankPUB-27240176
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 01HumanNot a test of Cerebrolysin aloneNon-randomized trialEfficacy outcome

    In chronic cerebral ischemia patients, mexidol with Cerebrolysin significantly reduced the severity of all major symptoms.

    In plain wordsIn patients with chronic cerebral ischemia, mexidol with Cerebrolysin reduced the severity of major symptoms.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseMajor symptom severity
    Study

    n = 36

    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Based on the results of clinical and neurological study, the efficacy of combination therapy with mexidol and cerebrolysin as long-term neuroprotection drugs was shown which manifested a significant reduction in the severity of all major symptoms under the influence of the therapy.
    2 context sentences
    Summary · context
    The study included 36 patients with CCI, II stage.
    Summary · context
    In addition to basic therapy, patients received two courses of the mexidol/cerebrolysin combination during 6 weeks with 3 month-interval between the courses.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.